Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0403 | Tetraferric tricitrate decahydrate

Molecular Formula C18H32Fe4O31
Molecular Weight 967.8
Structure
Clearance The rate of iron loss is approximately 1 mg/day [A32514]. The pharmacokinetic properties of ferric compounds vary.
Volume of distribution Less than 65% of iron is stored in the liver, spleen, and bone marrow, mainly as ferritin and haemosiderin [T28]. The pharmacokinetic properties of ferric compounds vary.
Route of elimination Iron is predominantly conserved in the body with no physiologic mechanism for excretion of excess iron from the body, other than blood loss [A32514]. The pharmacokinetic properties of ferric compounds vary.
Protein binding Fe3+ is converted to Fe2+, which is bound and transported in the body via circulating transferrin. In pathogenic _Neisseria_, ferric iron-binding protein serves as the main periplasmic-protein for ferric iron that has equivalence to human transferrin [A32523]. Once in the cytosol, ferric iron is stored in ferritin where it is associated with hydroxide and phosphate anions [A32525].
Half life The pharmacokinetic properties of ferric compounds vary.
Absorption Iron absorption and systemic iron homeostasis are regulated by hepcidin, which is a peptide hormone that also regulates the activity of the iron-efflux protein, ferroportin-1 [A32514]. Iron is mostly absorbed in the duodenum and upper jejunum [L2258]. Fe3+ displays low solubility at the neutral pH of the intestine and is mainly be converted to ferrous iron (Fe2+) by ferric reductases [T28], as ferric salts are only half as well absorbed as ferrous salts [L2258]. Once converted in the intestinal lumen, Fe+2 is transported across the apical membrane of enterocytes [A32514]. The absorption rate of non-haem iron is 2-20% [A32514]. Stored iron may be liberated via ferroportin-mediated efflux, which is coupled by reoxidation of Fe2+ to Fe3+ by ceruloplasmin in the serum or hephaestin in the enterocyte membrane [A32524]. Fe3+ subsequently binds to transferrin, which keeps ferric cation in a redox-inert state and delivers it into tissues [A32514]. It is proposed that there may be separate cellular uptake pathways for ferrous iron and ferric iron. While ferrous iron is primarily carried by divalent metal transporter-1 (DMAT-1), cellular uptake of ferric iron is predominantly mediated by beta-3 integrin and mobilferrin, which is also referred to as calreticulin in some sources as a homologue [A32507]. However, the most dominant pathway in humans is unclear [A32507].

V

V03AE08 Ferric citrate


[V03AE] Drugs for treatment of hyperkalemia and hyperphosphatemia


[V03A] ALL OTHER THERAPEUTIC PRODUCTS


[V03] ALL OTHER THERAPEUTIC PRODUCTS


[V] Various ATC structures


  • Q22075864 Q91187K011 UNII-Q91187K011
    tetraferric tricitrate decahydrate

    DrugBank Name Tetraferric tricitrate decahydrate
    DrugBank DB14520
    PubChem Compound 90478690
    ChemSpider 34993203